Savvy Advisors Inc. Boosts Johnson & Johnson Stake

Investment firm increases holdings in pharmaceutical giant by 43.5% in Q4 2025

Apr. 8, 2026 at 9:11am

Got story updates? Submit your updates here. ›

Savvy Advisors Inc., a financial advisory firm, has increased its stake in Johnson & Johnson (NYSE: JNJ) by 43.5% in the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 32,588 shares of the healthcare company's stock, valued at $6.74 million.

Why it matters

This move by Savvy Advisors highlights the continued investor confidence in Johnson & Johnson, a diversified healthcare conglomerate with leading positions in pharmaceuticals, medical devices, and consumer products. The stock's performance and growth potential have made it a popular choice among institutional investors.

The details

Savvy Advisors Inc. added 9,873 shares of Johnson & Johnson to its portfolio during the fourth quarter, bringing its total holdings to 32,588 shares. This represents a 43.5% increase in the firm's position in the company. Johnson & Johnson's stock has seen strong performance in recent quarters, driven by the success of its pharmaceutical and medical device divisions.

  • Savvy Advisors Inc. increased its stake in Johnson & Johnson in the fourth quarter of 2025.

The players

Savvy Advisors Inc.

A financial advisory firm that manages investments for its clients.

Johnson & Johnson

A multinational healthcare company that develops, manufactures, and markets pharmaceutical, medical device, and consumer products.

Got photos? Submit your photos here. ›

The takeaway

The increase in Savvy Advisors' stake in Johnson & Johnson reflects the continued investor confidence in the healthcare giant's ability to deliver strong financial performance and growth. As a diversified company with leading positions in multiple healthcare segments, Johnson & Johnson remains an attractive investment option for institutional investors seeking exposure to the healthcare sector.